From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
November 12, 2019
Philadelphia, PA, November 12, 2019– IntegriChain, a leading life sciences commercial data and analytics company that helps patients start therapy faster and stay on therapy longer, today announced that the Company has completed implementation of its Gross-to-Net (GTN) Managed Services with Akcea Therapeutics. IntegriChain GTN Solutions, which are built to industry best practices and are scalable and auditable, deliver end-to-end revenue management for Life Sciences Market Access and Finance teams that improves forecast accuracy, GTN modeling, and financial close efficiency. IntegriChain also is finalizing the implementation-readiness process for five additional GTN Managed Services customers.
“Gross-to-Net is the most critical financial challenge for Life Sciences manufacturers,” said Jennifer Sharpe, IntegriChain’s Segment Leader, Gross-to-Net. “Most manufacturers are bounded by spreadsheet-based processes, which is limiting, inefficient, and far too risky. With Gross-to-Net automation, manufacturers can improve margins and release surplus reserve back to P&L, reduce costs, mitigate spreadsheet risk tied to single points of failure, and drive decision making from data-driven insights. We are thrilled to partner with forward-thinking manufacturers such as Akcea to bring the power of GTN Automation live.”
“We have worked with IntegriChain since our first product launch one year ago,” said Melanie Morel-Ferris, Controller, Akcea Therapeutics. “During this time, IntegriChain has operated as an extension of both our Finance and Market Access teams and has become a trusted advisor. We are excited to have a live implementation of IntegriChain GTN Managed Services. Guided by their leadership in project management and subject matter expertise, we successfully developed the innovative processes and procedures necessary for financial reporting and forecasting in a commercial organization, allowing us to focus our efforts on our business of bringing drug therapies to patients as a result of our partnership with IntegriChain.”
About IntegriChain GTN Solutions IntegriChain GTN Accruals and GTN Forecasts solutions are end-to-end revenue management solutions for Life Sciences Market Access and Finance teams that:
GTN Accruals is pre-configured for all standard line items with robust out-of-the-box accrual methodologies, including inventory and pipeline adjustments to accruals, balance sheet reconciliation to the manufacturer’s ERP, and true-up functionality. GTN Forecasts is based on industry-standard forecast methodologies configured for each liability line item with the ability to execute multiple scenario analyses for forecasts along with functionality to compare scenarios.
IntegriChain Sponsors CBI GTN 2019 IntegriChain is a platinum sponsor of CBI GTN 2019, which begins today in Philadelphia. Throughout the conference, IntegriChain experts will share their GTN thought leadership:
INDUSTRY 101 BOOT CAMP: GTN Process Establishment and Best Practices Presenters: Jennifer Sharpe, Segment Leader, GTN; and Jeff Baab, Executive Director, Professional Services, IntegriChain
Leading Practices in GTN Management that Drive Success and Add Value Speaker: Jeff Baab, Executive Director, Professional Services, IntegriChain
Industry Insights on GTN Management Moderator: Jennifer Sharpe, Segment Leader, GTN, IntegriChain Panelists: Amy Diebler, Vice President, Finance & CFO, Chiesi USA Inc.; Jennifer Winterhalter, Vice President, Revenue Management, Amneal Pharmaceuticals; Anthony Fiordaliso, Vice President, Americas Finance, Astellas Pharma; Prakash Chainani, Vice President, Finance, IT and HR, Lifestar Pharma LLC (a Mankind Group Company); Tom Gayer, Vice President, Financial Planning & Analysis, Incyte; Jennifer English, Senior Director, Market Access, Pricing and, Gross-to-Net Financial Operations (FP&A), Insmed Incorporated
Structuring GTN — Groundwork and Process Design Within a Small or Early Commercial Company Moderator: Jennifer Sharpe, Segment Leader, GTN, IntegriChain Panelists: Kary Callahan, Associate Director, Commercial Finance, Paratek Pharmaceuticals; Bruce Greenberg, Corporate Controller, Karyopharm; Jake Burgess, Vice President and Controller, Kala Pharmaceuticals; and Funso Olufade, PhD, MBA, Director, US Commercial Finance, Amicus Therapeutics Inc.
About IntegriChain IntegriChain is a life sciences commercial data and analytics company that helps innovative bio/pharma manufacturers identify and remove barriers to patient therapy initiation and adherence. Our mission is to help all stakeholders in pharmaceutical access save as many patient days of therapy as possible. Our data-science-driven ICyte Platform and solutions uniquely focus on access challenges after the patient and provider commit to therapy. More than 165 life science manufacturers rely on insights delivered from IntegriChain’s data, analytics, and managed services to drive strategic decision-making and on-going business management across their payers, specialty pharmacies, patient services, and distribution channel partners. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. The company is headquartered in Philadelphia, PA, with offices in Ambler, PA; Somerset, NJ, and Pune, India. For more information, visit www.integrichain.com and our blog, or follow us on Twitter @IntegriChain and LinkedIn.
Contact Jennifer Guinan | Sage Strategic Marketing | 610.410.8111 | Jennifer@sagestrat.com
Save the date!
Webinars & Resources
See List
